Mendel Capital Management LLC Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

Mendel Capital Management LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,859 shares of the company’s stock after selling 203 shares during the period. Johnson & Johnson accounts for 0.9% of Mendel Capital Management LLC’s portfolio, making the stock its 27th biggest position. Mendel Capital Management LLC’s holdings in Johnson & Johnson were worth $1,436,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Holistic Financial Partners lifted its stake in Johnson & Johnson by 3.6% during the third quarter. Holistic Financial Partners now owns 3,598 shares of the company’s stock worth $583,000 after purchasing an additional 125 shares during the last quarter. Richard C. Young & CO. LTD. lifted its stake in Johnson & Johnson by 1.7% during the third quarter. Richard C. Young & CO. LTD. now owns 74,216 shares of the company’s stock worth $12,027,000 after purchasing an additional 1,237 shares during the last quarter. Equity Investment Corp lifted its stake in Johnson & Johnson by 1.2% during the third quarter. Equity Investment Corp now owns 86,613 shares of the company’s stock worth $14,036,000 after purchasing an additional 1,004 shares during the last quarter. Phillips Financial Management LLC lifted its stake in Johnson & Johnson by 6.7% during the third quarter. Phillips Financial Management LLC now owns 1,836 shares of the company’s stock worth $298,000 after purchasing an additional 116 shares during the last quarter. Finally, Aljian Capital Management LLC bought a new position in Johnson & Johnson during the third quarter worth $567,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.4 %

JNJ stock opened at $154.00 on Monday. The company has a market cap of $370.77 billion, a P/E ratio of 22.29, a PEG ratio of 2.74 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business has a fifty day moving average of $161.35 and a 200-day moving average of $156.13.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the prior year, the firm posted $2.66 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.22%. Johnson & Johnson’s dividend payout ratio is 71.78%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Citigroup increased their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley increased their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.